doi:10.1016/j.atherosclerosis.2019.01.024engBea, A.M.Lamiquiz-Moneo, I.Marco-Benedí, V.Mateo-Gallego, R.Pérez-Calahorra, S.Jarauta, E.Martín, C.Cenarro, A.Civeira, F.Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE geneART-2019-110894Background and aims: The aim of this work was to compared the effect of lipid lowering drugs among familial hypercholesterolemia (FH) subjects with a functional mutation in LDLR (LDLR FH) and FH with the p.(Leu167del) mutation in APOE. Methods: We retrospectively selected all adults with the p.(Leu167del) mutation on lipid-lowering treatment (n = 22) attending the Lipid Unit at the Hospital Miguel Servet. Age and sex matched LDLR FH from the same Unit were randomly selected as a control group (n = 44). Results: The mean percentage reduction in LDLc was significantly higher in the p.(Leu167del) carriers (-52.1%) than in the LDLR FH (-39.7%) (p = 0.040) when on high intensity statins. Similar differences between groups were observed in non-HDLc -49.4% and -36.4%, respectively (p = 0.030). Conclusions: Subjects with p.(Leu167del) mutation have a higher lipid-lowering response to statins with or without ezetimibe than LDLR FH. This supports the use of genetics for a more efficient management of FH.2019http://zaguan.unizar.es/record/8754010.1016/j.atherosclerosis.2019.01.024http://zaguan.unizar.es/record/87540oai:zaguan.unizar.es:87540info:eu-repo/grantAgreement/EUR/ISCII-ERDF/A way to make Europeinfo:eu-repo/grantAgreement/ES/MINECO/PI13-02507info:eu-repo/grantAgreement/ES/MINECO/PI15-01983Atherosclerosis 282 (2019), 143-147by-nc-ndhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccess